Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.
Abstract
Decades of research indicate mitochondria from Alzheimer’s disease (AD) patients differ from those of non-AD individuals. Initial studies revealed structural differences, and subsequent studies showed functional deficits. Observations of structure and function changes prompted investigators to consider the consequences, significance, and causes of AD-related mitochondrial dysfunction. Currently, extensive research argues mitochondria may mediate, drive, or contribute to a variety of AD pathologies. The perceived significance of these mitochondrial changes continues to grow, and many currently believe AD mitochondrial dysfunction represents a reasonable therapeutic target. Debate continues over the origin of AD mitochondrial changes. Some argue amyloid-β (Aβ) induces AD mitochondrial dysfunction, a view that does not challenge the amyloid cascade hypothesis and that may in fact help explain that hypothesis. Alternatively, data indicate mitochondrial dysfunction exists independent of Aβ, potentially lies upstream of Aβ deposition, and suggest a primary mitochondrial cascade hypothesis that assumes mitochondrial pathology hierarchically supersedes Aβ pathology. Mitochondria, therefore, appear at least to mediate or possibly even initiate pathologic molecular cascades in AD. This review considers studies and data that inform this area of AD research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondria, too, are damaged by oxidative and nitrosative stress in AD as noted [34].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of Aβ oligomers in mitochondrial membranes is consistent with Aβ-induced mitochondrial dysfunction occurring early in the disease progression timeline [34,53].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Oxidative stress from mitochondrial dysfunction and reactive oxygen species (ROS) accumulation further heightens neuronal vulnerability [6].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. S., Fahy, E., Shinobu, L. A., Galasko, D., Thal, L. J., Beal, M. F., Howell, N., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4526 · Cited by 341
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“plaques may arguably have AD; a current construct refers to this state as “preclinical AD” [144].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734 · cited 1×
“Due to the presence of the mutated mtPOLG transgene, these mice acquire excess somatic mtDNA mutations and mitochondrial dysfunction [65, 66].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundBloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · cited 1×
“In response to this, some now speculate A itself is insufficient to cause the disease, but instead initiates AD by triggering a critical change in tau biology [114, 119, 120].”
Background
Research works printed but not linked: 1
- Parker WD (1990) Sporadic neurologic disease and the electron transport chain: A hyothesis In Proceedings of the 1989 Scientific Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease, Pascuzzi RM, ed. Indiana University Printing Services, Bloomington, Indiana.
Cited by
Items 801–856 of 856
Medina, T., Quiñones, S., Liu, Z., Wu, L., Ziani, B., Shedlock, C. J., Ma, X., Ryan, A., Larson, R., Soto, C. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.16.732673
Wuyart, A., Martinez, A., Oudart, J., Mahmoudi, R., & Millot, J. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6c00294 · Cited by 1
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.05
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.references
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.07
Third Section: Design of a dimeric-nanobody specific for Aβ42 oligomers: the Dimeric-DesAb-O
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.06
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.03
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.04
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.02
Conclusion and Future Perspectives
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.08
Patient cerebral organoids capture Alzheimer’s disease proteomic biomarkers and drug targetsPreprint
Thomson, S., Li, X. C., Walker, S., Tang, T. C. Y., Graham, M. E., Olechnowicz, S. W. Z., Bowden, R. J., Waugh, K. A., Slawson, C. M., Burns, J. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.22.733874
Self-citationTargeting mtDNA to Modulate Mitochondrial Dysfunction in Neurodegenerative Diseases
Pramanik, S., Debnath, B., Chakraborty, A. J., Islam, A., Mullick, S., Chaudhary, P., Nath, R., Chellappan, D. K., Mondal, M., & Ashique, S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06008-2 · Cited by 1
“Cybrid cells, produced by the transfer of normal mitochondria into mtDNA-depleted cell lines [94], replicate the pathological bioenergetics characteristics of AD and PD [87].”
Saffron and its Bioactive Constituents as Mitochondria-Targeted Protectors Against Organ Injury
Pedramfar, F., Abolhosseini, A., D’Aiello, C., Pourbarkhordar, V., & Rahmani, S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06016-2 · Cited by 1
“Hallmark features include extracellular deposition of amyloid-β (Aβ) plaques, intracellular accumulation of hyperphosphorylated tau protein forming neurofibrillary tangles, synaptic dysfunction, oxidative stress, and neuroinflammation [28–30].”
Zhu, Q., Ye, N., Huang, L., Wang, H., Zhao, Q., Ma, L., She, G., Mu, L., & Shi, W. (2026) · Talanta · doi:10.1016/j.talanta.2026.130250
Venkei, Z. G., & Savelieff, M. G. (2026) · Exploration of neuroscience · doi:10.37349/en.2026.1006139
Aloe emodin attenuates Aβ 1–42 -Induced neurotoxicity in SH-SY5Y cells via downregulation of PPM1K
Huang, F., Guo, M., Yang, Y., & Wang, Z. (2026) · Open Medicine · doi:10.1515/med-2026-1473
“Mitochondria play a central role in maintaining neuronal energy homeostasis, regulating ROS production and calcium signaling, as well as controlling apoptotic pathways [11].”
Shan, H., Lu, G., Yuan, Y., Dong, Q., Fang, C., Yu, K., Chen, L., Wei, Z., Chen, H., Hu, L., et al. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6c00231
Acylglycerol Kinase Inhibition Restores Mitophagy and Alleviates Alzheimer's Disease Pathology
Li, W., Yu, X., Guo, C., Huang, Y., Wei, Z., Liu, Y., Wang, J., Liu, R., Ji, W., Duan, Q., et al. (2026) · MedComm · doi:10.1002/mco2.70863
“A β oligomers can interfere with autophagosomes, impeding their transport to mature endo-lysosomes [ 2, 8, 9 ].”
Jaiyeoba-Ojigho, E. J., Ilesanmi, T. M., Judith, E. N., Ochonogor, O. O., Lilian, C.-O. E., Olawale, O. A., Ijeboi, S. O., & Okolie, I. E. (2026) · Book Publisher International (a part of SCIENCEDOMAIN International) · doi:10.21203/rs.3.rs-10229452/v1
Astrocytic lactate shuttle disruption and the energy-starved lysosome in Alzheimer's diseasePreprint
Kim¹, Y., Heo, W., Park, S. J., Kim, Y., & Cho², Y. E. (2026) · Research Square · doi:10.21203/rs.3.rs-10057949/v1 · Cited by 1
Alhowail, A. H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1895764
“Experimental data suggest that dapagliflozin may improve redox balance, reduce lipid peroxidation, and support mitochondrial efficiency under conditions of metabolic overload (El-Safty et al., 2022; Samman et al., 2023; Swerdlow, 2018).”
InfluentialSavignac, C., St‐Onge, F., Villeneuve, S., Badhwar, A., Taliun, S. A. G., Farhan, S., Geddes, M. R., Medina, Y. I., Poirier, J., Spreng, R. N., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102943
“60 In vitro analyses have suggested that A β 42 peptides could act as a neurotoxin to induce oxidative stress, which impairs mitochondrial functioning.”
Xiao, L., Green, J. M., Mochizuki, M., & Nakahara, T. (2026) · Cells · doi:10.3390/cells15151368
“A β , hyperphosphorylated tau, activated glia, and dysfunctional mitochondria further amplify oxidative stress through excessive mitochondrial ROS production and increased NADPH oxidase (NOX2/NOX4) and inducible nitric oxide synthase (iNOS) activity [93,101–103].”
Neuroprotective mechanism of Ribisin A on Aβ25–35-induced PC12 cell damage model
Du, X., Bao, M., Li, Y., Ding, J., Zhang, Z., Chen, H., & Liu, Y. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103825
Muhammad, N., Ai, R., Yang, L., Cui, Y., Wang, L., Weng, S., Wang, Y., Kakar, M. U., Khan, S., Ahmad, S., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1877358 · Cited by 2
“It can initiate pathologic cascades by shifting APP processing toward amyloidogenesis, as supported by cybrid studies, bioenergetic alterations in peripheral non-degenerating tissues, and links between mitochondrial failure and plaque deposition (Swerdlow, 2018).”
A peripheral perspective on brain health: vascular and skeletal muscle contributions
Keller, J. L., Pennartz, K. J., Sprick, J. D., Hein, E. J., Irving, B. A., Vann, C. G., Butlig, E.-A. R., Al-Masri, S., & Nelson, A. R. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00462.2026 · Cited by 1
Klinman, E., Kwon, J.-S., Dolle, R. E., Pak, S. C., Silverman, G. A., Perlmutter, D. H., & Yoo, A. S. J. (2026) · Autophagy · doi:10.1080/15548627.2026.2719435 · Cited by 1
Chen, J., Chen, X., Yu, W., Chen, T., Liu, Z., & Hu, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1933454
“…and experimental studies have demonstrated that increased oxidative stress and altered energy metabolism are associated with amyloid-β aggregation, tau hyperphosphorylation, and synaptic dysfunction—all hallmark features of AD (Dhapola et al., 2024; Butterfield et al., 2001; Swerdlow, 2018).”
Thakur, A., Sharma, R. R., Kumari, S., Prakash, D., & Devi, A. S. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02371-7
“…on amyloid-β (Aβ) and phosphorylated tau (p-tau) on mito - chondrial protein import, damage to mitochondrial DNA (mtDNA) further contributes to an increase in the generation of reactive oxygen species (ROS), bioenergetic dys - function, and neuronal dysfunction (Swerdlow 2018; Zhao et al. 2024).”
Transcriptomic signatures as biomarkers for the progression of mild cognitive impairment
Yang, J., Li, J., 毛柳元, Ren, H., Li, Q., Geng, X., Lu, Q., Peng, C., Zhang, J., Liu, X., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1901264
“…exhibited significant enrichment in pathways related to “mitochondrial inner membrane,” “synapse,” “ribosomal function,” and “Alzheimer’s disease,” consistent with the notion that mitochondrial dysfunction and synaptic impairment are early hallmarks of AD (Li et al., 2025; Swerdlow, 2018).”
Samaiya, P. K., Agrawal, A., Kesharwani, S., Sathe, R., Prajapati, S. K., & Majumdar, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889898 · Cited by 1
“…particular problem to neurons, as they have high metabolic needs, low regenerative capability, and a large amount of lipids; oxidation of proteins, lipids, and mtDNA, which is without histone protection and lacks repair mechanisms, causes impairment in ATP synthesis and apoptosis (Swerdlow, 2018).”
Alzheimer’s Disease in the Era of Geroscience: Mechanisms, Biomarkers, and Therapeutic Prospects
Chmielewski, P. P. (2026) · Cells · doi:10.3390/cells15171599
“Decline in these systems can become self-reinforcing: aggregates burden clearance mechanisms, impaired clearance increases aggregate load, and damaged mitochondria elevate oxidative stress and reduce ATP supply [72–75].”
Cai, J., Luo, J., Cai, Y., Xu, Y., Ran, R., Xiao, M., Ye, Q., Zheng, W., & Li, S. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112879
Vallés, A. S., & Barrantes, F. J. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1860052
“Such deficits align with the neuroenergetic hypothesis of Alzheimer disease, in which chronic or intermittent energy failure contributes to synaptic dysfunction and neuronal loss (104, 105).”
Islam, M. S., Islam, M. T., Mondol, M., Islam, I., Fuad, K. M., Abid, M. F., Tajim, S., & Ferdous, R. (2026) · Advances in Redox Research · doi:10.1016/j.arres.2026.100196
Otoda, T., Nakajima, H., & Takayama, T. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2026.1892506
“Recent conceptual frameworks pro-pose that neurodegenerative disorders may be understood, at least in part, as systemic diseases driven by impaired mitochondrial biology and disrupted stress adaptation (Shpilka and Haynes, 2018; Swerdlow, 2018).”
Abdulrahman, H. N., & Hassan, L. M. (2026) · Academic Journal of International University of Erbil · doi:10.63841/iue33118
“…mitochondrial abnormalities, including physical injury, decreased electron transport chain (ETC) activity, and increased oxidative stress [2] To guarantee effective ATP generation and consistent intracellular energy transfer, CK collaborates with mitochondrial creatine kinase (mtCK), an…”
Phytotherapeutic targeting of mitochondria in Alzheimer’s disease: A narrative review
USMAN, I. M., Adeniyi, I. A., Asekenye, C., Ugwu, O. P.-C., Ikwuka, D. C., Muhidin, H. A., Wali, C. C., Diaz, M. E. F., & Archibong, V. (2026) · Phytomedicine Plus · doi:10.1016/j.phyplu.2026.101044
Peroxisomes in Alzheimer’s disease: emerging mechanistic insights and therapeutic opportunities
Liu, T., Liu, Y., Zhang, Y., Wang, J., Ren, Y., Fu, S., Han, L., 蒋鹏成, Chen, J., Li, Y., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1960320
“A combined-stress model predicts reduced ATP availability, increased lipid and ROS burden, and impaired organelle turnover, but direct causal evidence in sporadic human AD is not yet available (Fang et al., 2019; Kerr et al., 2017; Lin and Beal, 2006; Swerdlow, 2018; Wang et al., 2009).”
Hou, J., Yang, K., Zhang, D., Ba, Y., Wang, Y., Zhao, C., Zhu, N., & Gu, M. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05934-1
Nguyen, T., Woods, C., Liu, J., Wang, C., Lin, A., & Cheng, J. (2026) · Bioengineering · doi:10.3390/bioengineering13101113 · Cited by 1
“Growing evidence suggests that metabolic dysregulation and mitochondrial dysfunction play important roles in AD pathophysiology, including impaired energy metabolism, oxidative stress, and neuronal vulnerability [50,53].”
Lakra, A., & Kumar, P. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-02061-1
“…phosphorylation enrichment indicates mitochondrial dysfunction that impedes ATP production needed for 26 S proteasome activity and results in generation of ROS, which oxidatively modify proteasomal subunits and decrease the hydrolytic throughput (Swerdlow 2018); Yao et al. 2009); Stefanis 2012).”
Cardiorespiratory fitness is associated with cerebral oxygen extraction in Alzheimer’s disease
Kueck, P. J., Green, Z. D., Camones, R., John, C. S., Honea, R. A., Burns, J. M., Vidoni, E. D., & Morris, J. K. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1943472
“Impaired brain glucose metabolism (de Leon et al., 2001; Phelps and Mazziotta, 1985) and mitochondrial dysfunction (Swerdlow, 2020; Swerdlow, 2018). are well established and at the cellular level, AD is associated with reductions in mitochondrial number and size (Baloyannis, 2006; Brown et al.,…”
Bao, L., & Eer, D. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1937419
“Mitochondrial dysfunction is strongly implicated in AD (Swerdlow, 2018; Reddy and Beal, 2008).”
Kim, N., Jeong, D. S., Lee, Y., & Oh, C.-M. (2026) · Research Square · doi:10.21203/rs.3.rs-11103693/v1
窦报敏, Chen, J., Zhao, H., Sun-Yan, A., Zhu, X., & Xu, Y. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109130
Lemon, N. L., Canepa, E., Vázquez‐Torres, R., Parodi‐Rullán, R. M., Hirt, T., Petersohn, L., Rifat, T., Abyaneh, M. H., Ilies, M. A., & Fossati, S. (2026) · Science Advances · doi:10.1126/sciadv.ady1161 · Cited by 1
“However, mitochondria-targeted therapies have not yet reached FDA approval for these diseases ( 14 , 55 , 56 ).”
Matei, C., Palade, N. A., Dobri, A.-M., Dumitriu, D. O., Mutu, C., Popescu, A., Pintea, A. L., & Atasie, D. (2026) · Life · doi:10.3390/life16101749
“In LOAD, multiple studies have demonstrated impaired mitochondrial respiration, reduced ATP synthesis, increased oxidative stress, and disrupted mitochondrial dynamics, compromising neuronal energy supply and increasing vulnerability to excitotoxic and metabolic stress [172].”
BNIP3L/NIX-mediated mitophagy limits Alzheimer’s disease pathology and preserves neuronal functionPreprint
Li, Y., Ploumi, C., Volbracht, C., Tian, W., Kalogeraki, N., Kitopoulou, K., Navarro, C. C., Li, Z., Cherbuin, N., Tavares, L. C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.18.759942
Amyloid-β peptide and mitochondrial dysfunction
Yang, A. J. T., & Wilkins, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45078-5.00022-1
Mitochondria as a toxicological target for fungicides
da Silva, M. G. R., Mendes, D., Oliveira, M. M., Andrade, P. B., Videira, R. A., & Peixoto, F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45078-5.00039-7
Yousuf, S., Atif, F., & Stein, D. G. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261498338
Sindhu, N., Jain, S., Sharma, S. K., & Paliwal, S. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00379
Impact of post-translational modifications in Alzheimer’s disease: An overview
Venkataramaiah, C. (2026) · Current Proteomics · doi:10.1016/j.curpro.2026.100189
Gao, C., Shi, R., Jiang, X., Chai, H., & He, X. (2026) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2026.126237
Metadata
- Authors
- Swerdlow, R. H.
- Affiliations
- University of Kansas (US)
- Corresponding author
- Swerdlow, Russell H.
- ORCID
- Swerdlow, Russell H.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-10-07
- Volume
- 62
- Issue
- 3
- Pages
- 1403-1416
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5869994
- OpenAlex
- W2764071986
- Cited by
- 850
- References
- 154
- Citations by year
- 2026: 126 · 2025: 106 · 2024: 97 · 2023: 110 · 2022: 122 · 2021: 114 · 2020: 106 · 2019: 49 · 2018: 18 · 2017: 1
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG035982)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, mitochondrial dysfunction
- MeSH terms
- Alzheimer Disease, Animals, Humans, Mitochondria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.